Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
C. Arndt, J. Stoner, D. Hawkins, et al. (2009). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 327 times. https://doi.org/10.1200/JCO.2009.22.3768
Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
